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1. Introduction 
Neurocysticercosis (NCC) is a biological marker of poverty and underdevelopment [1]. The 
frequency of this brain parasitic disease is probably high worldwide, as well as epilepsy; 
however, little is known about the natural history of the infection in humans. Both, NCC 
and epilepsy, are an increasing burden on the welfare and economy of developing countries 
[2]. This is why knowledge of these diseases should be improved, in order to prevent them.  
Acute symptomatic seizures are the most common clinical manifestation of NCC in those 
patients in whom a cysticercus is located in brain parenchyma [1-3]. Epilepsy attributable to 
NCC usually has a good prognosis in terms of seizure control and seizure remission [1,4]. 
Although some authors have suggested that anticysticercal treatment is associated with 
reduced seizure recurrence, there is no evidence that cysticidal treatment does more good 
than harm in addition to conventional antiepileptic treatment [2,5 ] According to new 
information, the traditional view of the relationship between NCC and epilepsy [2,3] can be 
questioned. Nowadays, NCC is considered a comorbid component of epilepsy [6]  
2. Epidemiology of neurocysticercosis and epilepsy 
In developed countries, the age-adjusted incidence of epilepsy ranges from 24 to 53/100,000 
[7]. In developing countries (DC) the incidence of epilepsy on the basis of two studies 
carried out in South America in the last decade, ranged from 114 to 190/100,000 [8]; 
considerably higher than that reported in industrialized countries. New studies carried out 
in the last few years confirm high incidence: A hospital-based study of children in Tunisia 
reported the incidence of first unprovoked seizures to be 102/100,000 [9]. A population-
based study carried out among children in Kenya, reported the incidence of epilepsy (two or 
more two unprovoked seizures) to be 187/100,000 [10]. In a population-based study among 
all ages in Honduras, Central America [11], the incidence of patients with non-febrile 
seizures was 92.7/100,000. Because of the broader case-inclusion criteria and uncertainty 
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regarding age-specific distribution in these studies, there is no way to compare results from 
these incidence studies. Nonetheless, the incidence of epilepsy is probably higher in DC 
than in industrialized countries [7]. 
Reported prevalence of active epilepsy, based on methodology recommended by the 
International League Against Epilepsy (ILAE) Commission of Epidemiology and Prognosis 
[12] in DC, ranges from 3.9 to 15.7 per 1,000 person-years [13] These differences, however, 
are due to different approaches used by the studies and differences regarding the definitions 
of active epilepsy: Limiting assessment to those studies that provide information for age-
adjusted rates, the average age adjusted prevalence of active epilepsy is 8.5/1,000, which is 
similar to the developed countries. This prevalence is low given the high incidence of epilepsy 
in DC and may be due to the fact that mortality of people with epilepsy is higher in 
comparison with that of developed countries. While studies from developed countries show a 
consistent pattern suggesting that the onset of epilepsy occurs at both extremes of life [7]; on 
the other hand, incidence in DC is highest among young and middle-aged adults [13], perhaps 
as a manifestation of diseases prevalent in these age-groups. This includes conditions such as 
brain injury and infectious and parasitic diseases endemic in these countries. 
Taenia solium infection is widely endemic in poor countries, both in highlands or tropical 
areas, in Central and South America, and non-Muslim populations of Asia and Africa [1]. 
Cysticercosis is considered an emerging infectious disease in some developed countries; 
persons who have never left the United States as well as visitors to disease-endemic regions 
are at risk [2]. Data on the frequency of NCC from endemic countries have been compiled 
from clinic-based patients or autopsied cadavers. NCC was found, for example, in 2.8%-
3.6% of all autopsies in some hospitals [14]. However, such statistics can be misleading 
because differences in availability of medical services and lack of comprehensive and 
consistent reporting in most countries still confound attempts to compare incidence and 
prevalence among countries [15]. Most reports fail to provide even minimal information 
regarding diagnostic criteria and definitions; consequently, these data are definitely biased 
and hardly representative of the general population. 
Immunoserologic assays, such as enzyme-linked immunoelectrotransfer blot assay (EITB) or 
enzyme-linked immunosorbent assay (ELISA), detect antibodies against T. solium or 
cysticercus [1] Epidemiological surveys for human cysticercosis, using EITB as a marker of 
infection, report a seroprevalence from 8% to 12% in some regions of Latin American [16,17]. 
These assays are useful for identification of individuals who have had systemic contact with 
the parasite at some time. Seropositivity, however, does not necessarily mean an active 
systemic infection or central nervous system (CNS) involvement at any time [1,18]. Most 
seropositive individuals in these populations were asymptomatic. There are no prospective 
cohort studies providing information on the proportion of seropositive individuals that will 
develop seizures or other neurological symptoms. Some studies [17], but not all [19] have 
reported an association between seizures and seropositivity. Although a higher proportion 
of patients with epilepsy have been shown to be EITB positive when compared to those 
without epilepsy, the proportion of seropositivity in epileptic patients is similar to that 
reported in the general population in these same areas [17].  
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3. Definitions of epileptic seizures, epilepsy and neurocysticercosis 
In order to understand the relationship between epilepsy and NCC, it is crucial to promote 
consistency in definitions to enhance research studies, facilitate comparison between 
populations, provide data useful for detection, treatment, and prevention, and to promote 
effective health care for people with epilepsy and NCC [2].  
The natural history of the cysticerci in the CNS is not entirely understood. Computed 
tomography (CT) and magnetic resonance imaging (MRI) have been useful in the study of 
the evolution of the cysticercus within the brain parenchyma [20]. Once the oncosphere has 
passed into the parenchyma, it grows and evolves through vesicular, colloidal, granular-
nodular, and calcified phases [21]. In the vesicular phase the host tends to show immune 
tolerance, and in most cases there is no surrounding parenchymal reaction; the larva lives 
inside a translucent liquid-filled cystic structure surrounded by a thin membrane, where it 
can remain viable from a few months to several years [22] The CT scan depicts 
circumscribed, rounded, hypodense areas, varying in size and number, without 
enhancement by contrast media [20].With the MRI, the vesicular larva appears with a CSF-
like intensity signal on all sequences, with no surrounding high signal on T2-weighted 
images. Both MRI and CT may show a high intensity, 2-3 mm. mural nodule, depicting the 
scolex, in the interior of some parenchymal vesicular cysts.  
As the cyst degenerates, it goes through a transitional stage: the contrast enhanced CT scan 
shows an annular (colloidal phase) or nodular [nodular phase) enhancement surrounded by 
irregular perilesional edema [1,20,22]. In this stage, the fluid content gives slightly higher 
signal than CSF and is sometimes isodense with the parenchyma on MRI-T1 and/or proton 
density-weighted, and high signal on T2 images. The capsule shows higher signal than the 
adjacent brain with thick ring enhancement on T1 images, while on T2 images there is a low 
ring signal surrounded by high signal lesion, due mostly to edema. Although these 
pathological changes are responsible for clinical manifestations, usually seizures and 
headache, they may not cause symptoms at all. Finally, when the cyst dies it may disappear 
or become an inactive calcified nodule of homogenous high density on CT, or low intensity 
on proton-weighted MRI [1]. 
Based on the abovementioned concepts a classification based on the viability and location of 
the parasite in the CNS of the host has been proposed: active, when the parasite is alive; 
transitional, if it is in the degenerative phase; inactive, if there is evidence of its death [20]. 
Each viability category was subdivided into parenchymal and extraparenchymal forms. The 
viability criterion is very important, as it allows us to analyze the natural history of the 
parasite, and, according to the parasite’s evolutionary stage, the production of 
physiopathological changes in the host’s CNS. On the basis of this classification, it is 
possible to relate clinical manifestations and therapeutic procedures to each category of the 
proposed classification. For example, seizures are the main symptom in the transitional 
parenchymal form due to the brain inflammatory reaction, whereas cranial nerve 
abnormalities and intracranial hypertension syndromes are more frequent in the 
subarachonoid and intraventricular forms.  
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According to the definitions suggested by the International League Against Epilepsy’s 
Epidemiology Commissions [6,12] , epilepsy is defined as two or more unprovoked seizures 
occurring at least 24 hours apart. Unprovoked seizures may occur subsequent to a well-
demonstrated antecedent condition, known to substantially increase the risk of epileptic 
seizures. New terminology and concepts proposed by the ILAE divide the causes of 
epilepsy into three broad categories: genetic, structural/metabolic, and unknown [23]. "The 
cause is considered structural/metabolic when a structural lesion (either static or 
progressive) or metabolic condition (e.g., inborn errors of metabolism) is present and is 
known to be associated with an increased risk of epilepsy.” The cause is attributed to the 
condition that is most directly linked and proximate to the development of epilepsy, for 
example NCC, in the calcified phase. 
An epileptic seizure is defined as ‘‘a transient occurrence of signs and/or symptoms due to 
abnormal excessive or synchronous neuronal activity in the brain’’ [24]. Epileptic seizures, 
even if recurrent, are not always synonymous with epilepsy per se [6]. Provoked or acute 
symptomatic seizures are seizures which occur ‘‘in close temporal association with an acute 
systemic, metabolic, or toxic insult or in association with an acute central nervous system 
(CNS) insult (infection, stroke, cranial trauma, intracerebral hemorrhage, or acute alcohol 
intoxication or withdrawal),’’ [12,25]. Such seizures are often isolated epileptic events 
associated with acute conditions, but may recur if the acute condition recurs, as happens in 
the transitional or degenerative form of NCC, due to the underlying inflammatory process 
The interval between the insult and the seizure—which is used to separate acute 
symptomatic from unprovoked seizures—may vary according to the underlying clinical 
condition [23,25] . In the NCC case, this interval lasts while the inflammation signs due to 
the transitional or degenerative cysts persist (six months on average). Nonetheless, if 
seizures occur in the presence of parasites in viable or calcified phase, they are unprovoked 
and, if recurrent, should be considered epilepsy [1-3].  
Seizures associated with NCC may be categorized as either acute symptomatic or as remote 
symptomatic seizures. Individuals with cysticerci in the transitional form or degenerative 
phase develop acute symptomatic seizures due to the acute inflammatory response of the 
brain; on the other hand, a patient with seizures who has active, viable cysts and/or inactive, 
non-inflammed calcified parasites may be categorized as having unprovoked seizures [3]. 
NCC has an unpredictable clinical course, which makes it difficult to categorize all cases 
into the proposed classification of the ILAE Commission. For instance, a patient with 
chronic recurrent seizures, whose imaging studies show several non-inflamed parenchymal 
calcifications, should be categorized as having remote symptomatic unprovoked seizures. 
The same patient, some years later, can experience a recurrence of parenchymal transitional 
cysts. This case should be considered to have multiple episodes of NCC now resulting in 
acute symptomatic seizures.  
The recent ILAE report defines comorbidity as the co-occurrence of two or more separate 
medical conditions in the same individual and includes NCC as a comorbid condition 
associated with epilepsy [6]. Ultimately, in patients with NC, what matters most is to 
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differentiate between provoked or acute symptomatic seizures and recurrent unprovoked 
seizures (epilepsy). This differentiation is very important, due to its implications concerning 
treatment and prognosis, as will be discussed below. Presumably, the inclusion of people 
with only acute symptomatic seizures as cases of epilepsy is one of the reasons for the high 
proportion of epilepsy reported in some studies [13].  
4. Seizures as a main clinical manifestation of neurocysticercosis 
In spite of the clinical heterogeneity and variability in the clinical forms of expression and 
evolution of NCC, all reports of medical literatures agree that seizures are the most common 
symptom of NC, occurring in 70-90% of patients [18,26]. However, seizure is more frequent 
when the parasite is located in the brain parenchyma of the patient, in comparison with the 
intraventricular or subarachnoid locations [20]. There is no uniformity in the reported 
distribution of seizure types in patients with NC. Some authors report a higher proportion 
of partial seizures, others conclude that generalized seizures are more frequent [1, 5, 27]. It 
seems that either generalized seizures or partial seizures with secondarily generalization are 
most commonly reported, while complex partial seizures are less frequent [1] 
Seizures may occur at any evolutionary stage of the parasite. A recent prospective cohort 
study [28], whose aim was to describe seizure as a presenting symptom in individuals with 
recently diagnosed neurocysticercosis showed that most of the seizures in patients in the 
youngest age category (3–24 years old) appear to be provoked or acute symptomatic 
seizures due to transitional cysts in the brain parenchyma rather than new onset idiopathic 
ones. Thus, it appears that children are more likely to have NCC-related seizures than 
adults. The authors found transitional cysts to be associated with a significantly higher 
probability of seizure in the chi-square analysis; however, in the regression models that 
adjusted for patient age and gender as well as the number and location of the cysts, no 
specific cyst phase was found to be significantly associated with having seizures. Patients 
with cysts in the parietal lobe and with cysts in the frontal lobe were also more likely to 
present seizures. 
It has been suggested that both age and gender influence the strength of the host’s immune 
response. In a recent study [29] the odds of having transitional cysts were found to be 1.5-
fold higher for the female patients than for the male; additionally, the number of transitional 
cysts was found to be 1.8-fold higher in the female patients than in the male, and this gender 
effect was not only statistically significant but also constant over time. It therefore appears 
that there are significant gender and age differences in the local immune response to NCC, 
even after adjusting for differences in healthcare access. 
Some studies have also found familial aggregation of NCC infection [17, 30], as well as 
regional differences in the clinical manifestations of human NCC may indicate a role of host 
genetics [31]. However, in a recent study that investigated whether there is familial 
aggregation of seizures in first-degree relatives of NCC patients with seizure versus NCC 
patients without seizure as presenting symptom in a group of patients in Ecuador [32], there 
was no trend toward familial aggregation of seizures in NCC patients.  
 Novel Aspects on Cysticercosis and Neurocysticercosis 294 
Neurologists from developing countries frequently see patients in whom the first seizure 
occurred many years before consultation; and when the second seizure occurs at the time of 
consultation, the imaging study shows one or more calcifications and one cyst in the 
transitional form with perilesional edema. We can assume that when the first seizures 
occurred, the patient had cysts in a transitional form, which eventually became calcified, 
and currently the patient has new acute seizures [1]. According to the ILAE Commission we 
should categorize these patients as having isolated epileptic events associated with a 
recurrent acute condition (transitional form) [3].  
So far, the mechanism by which the calcified neurocysticercal lesions (CNL) cause seizures 
or epilepsy is not known [1,33,34] This has been attributed to residual perilesional gliosis 
that results in chronic epileptogenic foci [33]. CNL are frequently encountered on CT scans 
of asymptomatic individuals, and studies from Latin American countries report that the 
majority are incidental lesions [30,35] These observations would question the 
epileptogenicity of CNL. On the contrary, based on epidemiological studies, patients with 
epilepsy have a higher prevalence of calcified lesions than controls [19].  
Another potential evidence for the epileptogenicity of CNL is the episodic appearance of 
edema surrounding the CNL after seizures. Some studies have suggested that perilesional 
oedema is associated with episodic seizure activity in patients with CNL [36] . The authors 
argue that episodic release of cysticercal antigens from the calcified lesions can lead to 
inflammation, perilesional edema, and seizures. These studies have not been replicated so 
far. Anyway, it is not clear whether this edema is causal or a consequence of the seizure [34]. 
Transient cortical edema after seizures, a rare neuroimaging finding, was described more 
than 20 years ago [37,38] but its mechanism has not been entirely clarified. The empirical 
observation of neurologists from NCC endemic countries is that perilesional oedema around 
calcification in patients with epilepsy are extremely rare and, when it happens, perilesional 
oedema disappears in a few days without any additional treatment, except for antiepileptic 
drugs. 
Another study designed to analyze epileptogenesis in calcified neurocysticercosis using 
dynamic contrast-enhanced MRI [39], reported quantitative differences between 
symptomatic and asymptomatic groups in various perfusion indices. Median values of the 
rate transfer constant and leakage volume were higher in symptomatic patients than in 
asymptomatic patients, indicating a higher degree of blood brain barrier permeability in 
symptomatic individuals. This study also showed increased MMP-9 (R279Q) gene 
polymorphisms in subjects with seizures compared with those in asymptomatic and control 
subjects. Therefore, the epileptogenicity in patients with CNL could be related to degree of 
inflammation, which also may be partly determined by genetic factors. This study was 
carried out with a small sample of patients and should be confirmed in the future.  
Single enhancing lesion and seizures. A single enhancing lesion on CT (SECTL) or 
hyperintense lesion on MRI is a common finding in patients with newly identified seizures 
in developing countries [40,41]. The patients, mainly children and young adults, have some 
benign and transitory clinical manifestations, predominantly partial or partial secondary 
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generalized seizures, and occasionally Todd’s paresis or focal neurological deficits. These 
lesions have been attributed mainly to cysticercosis or to tuberculosis; however, similar 
lesions have been reported in other inflammatory pathologies such as pyogenic abscess, 
histoplasmosis, blastomycosis and sarcoidiosis, post-infectious vasculitis, and to primary 
and metastatic brain tumors. 
The natural history of these lesions usually takes one of two forms: it becomes isodense on 
CT, or isointense on MR, and then either resolves entirely, or a punctuate calcification may 
be left as a residue [41]. The time till resolution of the lesion is quite variable ranging from a 
few weeks to more than a year. SECTL are benign and tend to resolve spontaneously, 
without anticysticercal drugs or surgery, since the parasite is already in the degenerative 
phase and will eventually disappear or become calcified [1]. Treatment should be limited to 
medication required to control the acute symptoms, such as antiepileptic medication [2]. 
5. Neurocysticercosis as etiology of epilepsy 
Analytical studies designed to establish associations and determinants of epilepsy have been 
scarce in DC. Comparing results of studies of etiology is difficult because of differences in 
definitions and lack of diagnostic criteria [3]. Most studies lack information on the latency 
between the first acute symptomatic seizure and the first unprovoked seizure, as well as age 
at onset of seizures and age at diagnosis. In studying etiology, it is preferable to use incident 
cases, not prevalent cases, because one cannot distinguish the potential etiological factors 
that preceded the onset of epilepsy from those which occurred after the disease developed. 
Cause and effect become confused. This is why It is extremely difficult to compare results of 
studies of epilepsy due to NC. These studies are few, and are frequently targeted at all 
seizures, instead of epilepsy alone. There are broad differences in the definition of NC, as 
well as failure to define criteria for diagnosis of either seizures or epilepsy.  
Information available in developing countries shows that the proportion of idiopathic 
(60-70%) to symptomatic epilepsy (30-40%) is similar to that reported in studies from 
developed countries [8]. Among the symptomatic group, infection and parasitic diseases, 
particularly neurocysticercosis, perinatal brain damage, and head trauma are the most 
frequent disorders reported as a cause of epilepsy [5,42]. In a prospective cohort study of 
patients with newly-diagnosed epilepsy seen at the five main hospitals in the three major 
cities of Ecuador, perinatal brain damage (9%), neurocysticercosis (8.3%), central nervous 
system infections (4.2%), stroke (4.8%), and head trauma (4.2%) were the most frequent 
disorders reported as causes of epilepsy [42]. Although NCC is one of the most frequent 
antecedents among the symptomatic group, this disease is not necessarily the main cause of 
epilepsy, as has been previously suggested [11,17,43,44]. 
Hospital-based studies to analyze NCC as etiology of epilepsy are shown in Table 1. Studies 
of highly selected patients with seizures in neurologic services of hospital settings from 
some DC reported NCC as the main cause of epilepsy, accounting for 30% to 50% of patients 
[11,43]. In a study carried out in 212 patients with epilepsy, a rural sub-Saharan Africa area 
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endemic for porcine cysticercosis [45], 2.4% were identified as definitive and 11% had 
lesions highly suggestive of NCC, using CT scan as part of the diagnoses. In another study 
from Africa, 37% of patients with epilepsy had NCC [46]. In studies from India, in which 
acute symptomatic seizures were excluded, only 11% (47) cases with epilepsy had NC; 
conversely, in a study of 572 patients with acute symptomatic seizures 67% had SECTL [48]. 
Another study was carried out in India [49] to determine the etiologic role of NCC in a 
hospital-based sample in 1026 patients with epilepsies divided according to the ILAE 
epidemiological criteria. NCC was diagnosed in imaging studies in 59% of those with acute 
symptomatic seizures, but only 2.0% with prevalent epilepsy, and none of the cases of 
incident epilepsy.  
 
Author 
Country/year 
(reference) 
# 
Pts.
Case 
Ascertainment 
Type of study NCC 
(%) 
Medina et al 
México/1990 (11) 
100 All seizures, 
CT scan 
Prevalent cases 50% 
Del Brutto et al 
Ecuador/1991 (43) 
225 All seizures, 
CT scan 
Prevalent cases 40% 
Murthy et al 
India/1999 (48) 
572 Acute seizures 
CT scan 
Retrospect (SCTEL) 67 % 
Sawhney et al 
India/1996 (47) 
407 Single Sz. Excluded 
CT scan 
Prevalent and incident 
cases 
11 % 
Singh G, et al 
India/2006 (49) 
1026 Single, incident and 
prevalent seizures 
CT scan 
Single Sz Prevalent cases 
Incident cases 
59 % 
2 % 
0 % 
Table 1. Neurocysticercosis as etiology of epilepsy: Hospital-based studies 
The above mentioned studies confirm the necessity to differentiate between acute seizure 
and recurrent unprovoked seizures (epilepsy). It is likely that most of the patients with NCC 
have acute symptomatic seizures which do not necessarily evolve into epilepsy. Similarly, it 
is crucial to determine NCC as etiology of epilepsy in incident cases instead of prevalent 
ones. These are probably some of the reasons of over diagnosis of epilepsy in some hospital-
based studies [3] 
Community-based studies in which CT scan was used to diagnose NCC are shown in Table 
2. In a study carried out in Ecuador [43], the authors concluded that NCC is associated with 
one in three cases of epilepsy and was possibly the cause of the excessive proportion of 
epilepsy in that population. However, only three (8%) of 24 people with epilepsy had 
“definitive” NCC. Another community survey [44] carried out in Peru showed that 
seroprevalence (using the enzyme-linked immunoelectrotransfer blot (EITB) assay] was 
positive in 24.2% (200/825); 15 of 39 individuals with seizures (38.5%) had lesions compatible 
with NCC on CT scan. The authors concluded that brain CT abnormalities compatible with 
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NCC were more frequent in individuals with seizures and in those with positive EITB for 
cysticercosis. Most of the patients who were diagnosed with NCC in this study had only 
calcifications (half of them had just one calcification); however, it is well known that brain 
calcifications do not necessarily mean NC. The small population samples of the above 
studies do not allow generalizations.  
 
Author 
Country/year 
Patients with 
epilepsy 
Inclusion criteria Diagnosis of NCC NCC 
No. (%) 
Montano, et al Perú/2005 
(44) 
39 All seizures 
Prevalent cases 
CT scan, 
> 50% only 1 
calcification 
15 (38) 
Del Brutto, et al 
Ecuador/2005 (43) 
19 Recurrent 
seizures 
Prevalent cases 
CT scan, 
All pts had only 1 
calcification 
5 (26) 
Medina et al 
Honduras/2005 (11) 
100 Recurrent 
seizures 
Prevalent cases 
CT scan, 37(37) 
Table 2. Neurocysticercosis as an etiology of epilepsy: Community-based studies 
There are several studies in the medical literature that have reported an association between 
epilepsy and NCC based on positive serum antibodies to Taenia solium/cysticercosis 
[17,50,51]. Unfortunately, the presence of antibodies may indicate only previous exposure to 
or infection with the parasite, but not necessarily brain infection. This information has 
created some distortion in the current perception of NCC epidemiology. A systematic 
review of the literature on the frequency of NCC, diagnosed with neuroimaging, has been 
published [15]. Overall, 565 articles were retrieved and only 26 had reliable information to 
estimate the frequency of NCC in various populations worldwide. The authors concluded 
that the prevalence of NCC worldwide remains unknown; however, the proportion of NCC 
among persons with epilepsy was very consistent and estimated at 29.6% (95%CI: 23.5%–
36.1%) from 12 studies conducted in Latin America, Sub-Saharan Africa, and Southeast Asia. 
6. Inconsistencies in the relationship between neurocysticercosis and 
epilepsy 
There are clinical inconsistencies in the link between epilepsy and NCC. Parasite location 
may be remote from the apparent epileptogenic region [3]. There is also no correlation 
between the NCC burden of lesions and the severity of the epilepsy. Patients with severe 
refractory seizures may have only one calcified lesion; on the other hand, there are patients 
with multiple cysts or calcifications but no seizures.  
EEG has been found to be abnormal in 30-50% of patients with seizures due to NC. It is 
assumed that EEG findings have poor correlation with symptoms and CT lesions in patients 
with NCC [52.53]. A positive correlation between CT lesions and localizing or lateralizing 
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EEG abnormalities has been reported for only 15-30% of patients. Similarly, the correlation 
between seizure type and EEG abnormalities ranges from around 7% to 20% [53]. 
Discrepancies between clinical localization based on seizure semiology and location of the 
lesion on neuroimaging is a not uncommon feature in patients with NC. A non-causal 
relationship between epilepsy and cysticercosis in some cases might explain these apparent 
discrepancies [54,55]. Further prospective cohort studies, properly designed to study ictal 
and interictal EEG abnormalities in patients with seizures, correlated with the different 
evolutionary stages of the parasite, may clarify the relationship between NCC and epilepsy. 
The coexistence of hippocampal atrophy and extrahippocampal pathological abnormalities, 
such as cortical dysgenesis and gliosis, referred to as “dual pathology”, has been reported in 
5 to 30% of patients with medically refractory partial seizures [56]. Dual pathology implies 
that both lesions somehow interact with each other and contribute to epileptogenesis 
through mechanisms still poorly understood. Some authors have also attributed 
hippocampal sclerosis to NCC [54.57,58]. Patients with calcifications due to NCC and mesial 
temporal lobe epilepsy (hippocampal sclerosis) became seizure free after anteromesial 
temporal lobectomy, without resection of the cysticercotic lesion [35], suggesting the two 
phenomena are independent. The presence of CNL does not influence the clinical and 
pathologic profile of patients with hippocampal atrophy. An irritative zone in the temporal 
lobe is more relevant in determining the severity, symptomatology and frequency of 
seizures than the number and location of calcifications [59]. The possibility of dual 
pathology related to NCC needs further clarification in prospective cohort studies. 
NCC and epilepsy are common diseases in most developing countries. Because of their high 
prevalence, a causal as well as fortuitous relationship between the two conditions might 
exist [35,54,60] NCC is also an uncommon cause of intractable epilepsy, even in endemic 
regions and that it may only represent a coexistent pathology, according to a cross sectional 
study investigating the etiology of intractable epilepsy in 512 patients in Brazil [61]. 
7. Effect of antihelminthic drug treatment on recurrence of seizures 
Treatment for NCC with antihelminthic drugs (AHD) such as praziquantel and albendazole 
has been available for at least 25 years, and since then its use has been controversial. 
Praziquantel was used for the first time in México [62]. Albendazole was used for the first 
time in China [63] . 
To date, there are no controlled clinical trials to establish definitive doses and duration of 
treatment. A meta-analysis was published in 2005 [64], in which only 11 studies, among 764, 
were selected, only 6 with viable cysts and 5 with degenerative or coloidal cysts. The 
authors reported disappearance of viable cysts in 44% of patients who were treated with 
albendazole vs. 19% of the placebo group (p <0.025). They also reported disappearance of 
degenerative cysts in 72% of patients of the albendazole group, and 63 % of the placebo 
group, but there was no statistical significance (p <0.38). The Editors of the journal where 
this meta-analysis was published affirmed that selected studies were small and 
heterogeneous, and only 5 of 11 were good quality. They concluded that studies provided 
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limited evidence of a modest effect of NCC treatment, since the effects of cysticidal 
treatment on neuroimaging end points were relatively small (OR <2.2) . A recent Cochrane 
review [65] of 21 randomized controlled clinical trials of cysticidal therapy concluded that 
with adults with viable cysts the use of albendazole is associated with a decrease in the 
number of cysts but not in the recurrence of seizures lesions. 
One of the main reasons for which there is a lot of confusion in the medical literature and a 
supposed controversy regarding the effectiveness of AHD, is that most of the publications 
report “reduction of the number of lesions” as a valid endpoint to measure effectiveness of 
the treatment, which is misleading. We should wonder, for example, in the hypothetical 
event that a person with 10 viable cysts has been administered AHD, whether, as a 
consequence of the treatment, 8 parasite die (80% reduction of lesion/successful treatment?), 
but two cysts remain which may provoke seizures or headache: Is this a successful 
treatment? Maybe not. 
The appropriate end point to evaluate the effectiveness of AHD could be the disappearance 
of cysts. Strictly speaking, even in the case that treatment with AHD may kill all parasites in 
a patient, it is not possible to talk about “cure” because, as we know, most cysts once they 
die became calcifications, a permanent sequel, which could aggravate seizures long life If we 
compare those studies in which one of the end points to evaluate effectiveness of AHD is 
disappearance of cysts (table 3), including the results of the abovementioned meta-analysis, 
where about 30% to 40% of patients had disappearance of cysts [66-68]. Therefore, there is 
no controversy; we can affirm that, according to available evidence based medicine, AHD 
are effective in one third of patients, approximately. 
8. Risk of seizure recurrence in patients with neurocysticercosis 
Some authors report that NCC patients with acute symptomatic seizures have a good 
prognosis in terms of remission of seizures [69-73]; others report that most patients have a 
high risk of seizure recurrence, and suggest that prognosis improves after antihelminthic 
treatment. [66]. Prospective cohort studies have determined the risk of seizure recurrence 
after a first seizure due to NCC is between 17% to 56%, depending on the viability of the 
parasite. The risk is greater in the transitional forms and it diminishes in the viable or 
calcified forms [73-76]. Overall, the risk of seizure recurrence involves around one third of 
patients.  
It has also been suggested that seizure control in patients with NCC is improved and that 
the chance of remaining seizure-free after the withdrawal of antiepileptic drugs is greater 
after a course of AHD, when compared with seizure control in those in whom the disease is 
left untreated [66]. However, current reliable information has shown that AHD treatment in 
patients with seizures due to NCC is not associated with the recurrence of seizures at all 
[67,68] (Table 3). 
Regarding the duration for which antiseizure medication should be continued following an 
acute NCC episode, some clinicians routinely continue antiseizure medication for 1 year, but 
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shorter and longer intervals have been recommended [1]. One assumes that the risk of 
seizures is substantial as long as there is an active ongoing process as characterized by 
persistence of edema around the degenerating lesion. Because of this, CT scan is a useful tool 
for these treatment decisions. It is appropriate to monitor cyst activity with CT scanning and to 
continue antiseizure medication until resolution of the acute lesion. After this time antiseizure 
medication may be discontinued [1]. Seizures occurring in individuals after resolution of 
edema and resorption or calcification of the degenerating cyst should be considered 
unprovoked and, in this situation, long-term antiseizure medication is warranted.  
 
Author/year, 
reference 
Treatment groups 
(No. patients) 
Cysts 
disappearance* 
No./% 
Seizures recurrence** 
No./% 
Garcia H, et al. 2004 
(66) 
Albendazole (55) 
Placebo ( 54) 
21 (38%) 
8 (15%) 
32 (56%) 
32 (54%) 
Carpio A, et al. 
2008, (73) 
Albendazole ( 51) 
Placebo ( 50) 
18 (35%) 
6 (12%) 
19 38%) 
27 (48%) 
Das K, et al. 
2007 (68) 
Albendazole (148) 
Placebo (150) 
10 (7%) 
12 (8%) 
40 (27%) 
24 (16%) 
* CT scan at 6 months after finishing treatment 
** Seizures recurrence at one year follow-up 
Table 3. Effects of cysticidal drugs on resolution of parenchymal viable cysts and seizures recurrence in 
patients with neurocysticercosis (randomized, placebo-controlled studies) 
It seems that interpretation of risk of seizures after neurocysticercosis is difficult. These 
difficulties are increased in those patients who have mixed forms, including active, 
transitional, and calcified lesions. Further studies should be performed in order to estimate 
recurrence risk in those patients with seizures due to calcifications alone, in comparison 
with patients with acute seizures due to transitional cysts.  
9. Conclusions 
Epilepsy and NCC are common diseases in poor countries, and NCC is increasingly 
diagnosed in developed countries due to migration from endemic regions. However, 
reliable data concerning prevalence and incidence of NCC is lacking worldwide. 
Seizures are the most common symptom in patients with the parenchymal location of the 
parasite. Seizures may occur at any evolutionary stage of the parasite, but acute 
symptomatic seizures are more frequent in the transitional form, due to the inflammatory 
response of the brain. Most people with NCC have acute symptomatic seizures that do not 
necessarily evolve into epilepsy. This is one of the reasons that epilepsy is over diagnosed in 
some studies. The ILAE’s Commission on Epidemiology includes NCC as a comorbid 
condition associated with epilepsy. 
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There are inconsistencies in the link between epilepsy and NC. Because of the high 
prevalence of each condition, a causal as well as fortuitous relationship between the two 
pathologies might exist. NCC is not necessarily the main cause of epilepsy in endemic 
countries, although it is one of the most frequent antecedents among adult patients with 
symptomatic epilepsy.  
Several studies have reported an association between epilepsy and NCC based on positive 
serum antibodies to Taenia solium/cysticercosis. This information has created distortion in 
the perception of NCC epidemiology 
Seizures in the context of edema and a degenerative lesion should be considered acute 
symptomatic even if they occur many months after presentation. After resolution of the 
acute lesion antiseizure medication may be discontinued. Seizures occurring after resolution 
of edema or calcification of the degenerating cyst should be considered unprovoked and, in 
this situation, long term antiepileptic medication is warranted. There is no correlation 
between treatment with antihelminthic agents and seizure recurrence  
The prognosis of seizure in patients with NCC is good. In about two thirds of the patients 
with acute symptomatic seizures due to NCC the seizures do not recur [67] People with 
acute seizures NCC should be treated with antiseizure medication until cyst resolution on 
CT scan. The risk of seizure recurrence (epilepsy) occurs in the inactive or calcified form of 
NC. 
Recommendations: Further research should be undertaken in order to clarify: -the natural 
history of T.Solium/cysticercosis disease, -the variability of antihelminthic treatment 
efficacy, -the factors that contribute to clinical heterogeneity of NC, -immunological 
response of the host. It is also recommended to standardize a common methodology, 
including definitions, in order to propose new diagnoses criteria for NCC. 
Health authorities should focus on prevention and eradication of taeniasis/cysticercosis in 
order to decrease the number of individuals with seizures/epilepsy and other consequences. 
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